Celltrion Files for South Korean Approval of Keytruda Biosimilar CT-P51
Celltrion announced on August 24 that it has submitted a marketing authorization application to South Korea’s Ministry of Food and Drug Safety for...
Search results for "immuno-oncology drug"
GC Pharma’s Homegrown mRNA Vaccine Advances to Phase 2 Trials
GC Pharma announced on the 11th that South Korea’s Ministry of Food and Drug Safety has approved its Phase 2 clinical trial application for its...
SK Plasma Launches High-Dose Revolpag 75 mg to Simplify Thrombocytopenia Regimens and Cut Costs
SK Plasma announced on Sept. 1 that it has begun distributing Revolpag Tablets 75 mg in South Korea, expanding its...
Moderna’s Landmark mRNA Cancer Vaccine Phase 3 Success Spotlights Korean Biotech Ties
Positive late-stage clinical results for a personalized messenger RNA cancer vaccine developed by Moderna and Merck are...
Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27
Samsung Bioepis announced on Aug. 10 that it has submitted a marketing authorization application to South Korea's...
Timing of Immune Cell Entry Dictates Anti-Cancer Defense in Hard-to-Treat Brain Tumors
Some immune cells surrounding a tumor actively attack it, while others create conditions that help it survive.
Fueling the Future of Biohealth: InterBiz Forum Opens in Jeju With a Record 1,500 Tech Deals
The 24th InterBiz Bio Partnering & Investment Forum 2026, a premier biohealth technology deal-making event, opened...
Qurient’s Mocaciclib Opens New Combination Frontiers for Hard-to-Treat Breast Cancer
Qurient announced on June 29 that it presented key clinical data highlighting the mechanistic advantages of its...
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’
The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological...
MSD Bets $510M on High-Quality Data to Fuel Post-Keytruda AI Drug Discovery
MSD, which has long dominated the global cancer market with its blockbuster immuno-oncology therapy Keytruda, is...